Treace Announces First Surgical Cases Utilizing the SpeedAkin™ Anatomic Compression Implant
Rhea-AI Summary
Treace Medical Concepts (NASDAQ: TMCI) has announced the successful completion of first surgical cases using its new SpeedAkin™ Anatomic Compression Implant. This implant expands the capabilities of their SpeedPlate™ fixation platform, specifically designed for Akin osteotomies - corrective procedures commonly performed during bunion surgery.
The SpeedAkin™ implant features dynamic titanium compression to stabilize Akin osteotomies during healing, offering an anatomically contoured fixation solution that eliminates potential nickel allergy reactions associated with nitinol staples. This development complements Treace's existing bunion treatment portfolio, which includes their flagship Lapiplasty® and Adductoplasty® Procedures.
Positive
- Launch of new SpeedAkin™ implant expanding product portfolio
- Successful completion of first surgical cases with new implant
- Product advantages over existing solutions (elimination of nickel allergy risks)
Negative
- None.
Insights
The introduction of SpeedAkin™ represents a significant strategic advancement for Treace Medical Concepts, expanding their addressable market in the bunion surgery space. This launch is particularly noteworthy for three key reasons:
Market Expansion Strategy: By addressing Akin osteotomies, which are frequently performed alongside bunion corrections, Treace is executing a smart portfolio expansion that leverages their existing SpeedPlate™ technology. This approach allows them to capture more revenue per procedure while maintaining their focus on their core bunion correction market.
Technical Advantages: The SpeedAkin™ implant offers two distinct benefits: 1) The titanium composition eliminates nickel allergy concerns associated with traditional nitinol staples, potentially expanding the eligible patient population and 2) The anatomic design with dynamic compression capability may lead to better healing outcomes, which could drive surgeon preference and adoption.
Commercial Implications: This product launch strengthens Treace's competitive position by: - Creating additional barriers to entry through expanded IP portfolio - Increasing wallet share per procedure - Enhancing surgeon loyalty through a more complete solution set The endorsement from key opinion leaders like Dr. Shane suggests potential for strong initial adoption among existing Lapiplasty® users.
PONTE VEDRA, Fla., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced the successful completion of the first cases utilizing its SpeedAkin™ Anatomic Compression Implant.
The SpeedAkin™ implant broadens the procedural versatility of Treace’s flagship SpeedPlate™ fixation platform, which is advancing a new standard in bone fusion fixation. Akin osteotomies are corrective straightening procedures of the great toe commonly performed in conjunction with bunion surgery1. SpeedAkin™ offers surgeons a unique anatomic implant that delivers dynamic titanium compression to stabilize the Akin osteotomy during healing.
“The SpeedAkin™ implant leverages our proprietary SpeedPlate™ technology in a differentiated Akin osteotomy solution, further expanding our best-in-class bunion focused portfolio.” said John T. Treace, CEO, Founder and Board Member of Treace.
Surgeon design team member, Amber Shane, DPM, FACFAS, Department Chair and Residency Faculty at AdventHealth commented, “The SpeedAkin™ titanium compression implant provides my patients the benefits of anatomically contoured fixation and eliminates the potential for nickel allergy reaction associated with nitinol staples. SpeedPlate™ technology is a gamechanger for my Lapiplasty® and Adductoplasty® procedures - and I’m excited to extend these benefits to my Akin osteotomies, a procedure I perform frequently with my bunion corrections.”
Internet Posting of Information
Treace routinely posts information that may be important to investors in the “Investor Relations” section of its website at www.treace.com. The Company encourages investors and potential investors to consult the Treace website regularly for important information about Treace.
About Treace Medical Concepts
Treace Medical Concepts, Inc. is a medical technology company with the goal of advancing the standard of care for the surgical management of bunion and related midfoot deformities. Bunions are complex 3-dimensional deformities that originate from an unstable joint in the middle of the foot and affect approximately 67 million Americans, of which Treace estimates 1.1 million are annual surgical candidates. Treace has pioneered and patented the Lapiplasty® 3D Bunion Correction® System – a combination of instruments, implants, and surgical methods designed to surgically correct all three planes of the bunion deformity and secure the unstable joint, addressing the root cause of the bunion and helping patients get back to their active lifestyles. To further support the needs of bunion patients, Treace has introduced its Adductoplasty® Midfoot Correction System, designed for reproducible surgical correction of midfoot deformities. The Company continues to expand its footprint in the foot and ankle market with the introduction of its SpeedPlate™ Rapid Compression Implants, an innovative fixation platform with broad versatility across Lapiplasty® and Adductoplasty® procedures, as well as other common bone fusion procedures of the foot. For more information, please visit www.treace.com.
- TMC Data on file
Dr. Amber Shane is a paid consultant of the Company.
To learn more about Treace, connect with us on LinkedIn, X, Facebook and Instagram.
Contacts:
Treace Medical Concepts
Mark L. Hair
Chief Financial Officer
mhair@treace.net
(904) 373-5940
Investors:
Gilmartin Group
Vivian Cervantes
IR@treace.net
FAQ
What is the new SpeedAkin™ implant announced by Treace Medical (TMCI)?
What advantages does the TMCI SpeedAkin™ implant offer over traditional solutions?
How does SpeedAkin™ fit into Treace Medical's (TMCI) existing product portfolio?
When did Treace Medical (TMCI) complete its first SpeedAkin™ surgical cases?
